This site uses cookies to bring you the best experience. Find out more
Skip to main content

News

Find Out The Latest

You can keep in touch with exciting developments for The Oxford Science Park and its occupiers here.

Contact us on comms@oxfordsp.com if you would like to know more about any of these stories.

You can also keep up to date by following us on Twitter or LinkedIn  


Exscientia and MD Anderson Launch Strategic Collaboration to Leverage AI in Developing Novel Oncology Treatments

Effort aligns MD Anderson’s drug development expertise with Exscientia’s AI-driven patient-first precision medicine and drug discovery platforms OXFORD, England & HOUSTON, Texas--(BUSINESS WIRE)-- Exscientia plc (Nasdaq: EXAI) and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to align the patient-centric artificial intelligence (AI) capabilities of Exscientia with the drug discovery and... Read more

Jérôme Marzinski appointed as Chief Executive Officer

Seasoned medtech leader with a proven track record in scaling companies Oxford, UK – 7 November 2022 – OxSonics Therapeutics, a clinical-stage company focused on transforming cancer treatment through SonoTran®, its ultrasound-based drug delivery platform, announces that it has appointed Jérôme Marzinski as its Chief Executive Officer with immediate effect. Jérôme is a seasoned medtech leader, having held a variety of senior roles over a... Read more

OxSonics presents preclinical data demonstrating SonoTran® enhanced the delivery and efficacy of an oncolytic virus in a murine bladder cancel model

OxSonics presents preclinical data demonstrating SonoTran® enhanced the delivery and efficacy of an oncolytic virus in a murine bladder cancel model Data presented at the International Oncolytic Virus Conference (IOVC) from a collaboration with Turnstone Biologics. Oxford, UK – 25 October 2022 – OxSonics Therapeutics, a clinical-stage company focused on transforming cancer treatment through SonoTran®, its ultrasound-based drug delivery... Read more

Scancell signs Commercial License Agreement with Genmab

Scancell Holdings plc ("Scancell" or the "Company") Scancell signs Commercial License Agreement with Genmab Genmab granted worldwide license to anti-glycan monoclonal antibody generated via Scancell's proprietary GlyMab® platform, for the development and commercialisation of novel therapeutic products Scancell to receive from Genmab an upfront payment as well as potential milestone payments of up to $208 million for each product... Read more

Oxford Cancer Biomarkers announces European expansion of chemotherapy toxicity test & independent real-world evidence of patient benefit

ToxNav®, a CE-marked in vitro diagnostics product is now registered in the European database on medical devices (EUDAMED).  Independent study publication highlights patient benefits, cost-savings and opportunity for ToxNav® to address potential health inequalities in current approaches to DPYD testing. OXFORD, UK – 26th September 2022 – Oxford Cancer Biomarkers Ltd (OCB) announces that ToxNav®, its proprietary pharmacogenomics test for... Read more